- Evaluation of new agents in the treatment of Waldenstrom's macroglobulinemia (WM) and Multiple myeloma.
- In particular, I am interested in evaluating new targeted biological agents and autologous transplantation approaches for plasma cell and mature B-cell disorders, such as WM. As well, I am active in developing a uniform approach to fatigue and anemia in myeloma with a focus on disease-specific exercise programs.
- Medical education in hematology
- I am interested in the evaluation of time management skills within the CanMEDS roles in hematology training and the use of handheld personal devices (PDA) for clinical training.
Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras.
Bone Marrow Transplant. 2019 Sep 26;:
A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL).
Leuk Lymphoma. 2018 Oct 02;:1-10
A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL).
Leuk Lymphoma. 2018 Jun 19;:1-9
Kidney Int Rep. 2018 May;3(3):748-751
Curr Hematol Malig Rep. 2017 Mar 20;:
Evidence of preserved collagen in an Early Jurassic sauropodomorph dinosaur revealed by synchrotron FTIR microspectroscopy.
Nat Commun. 2017 Jan 31;8:14220
Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure.
Bone Marrow Transplant. 2014 Oct 6;
Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia.
Br J Haematol. 2014 Jun;165(5):731-3
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Br J Haematol. 2013 Aug;162(4):483-8
Br J Haematol. 2013 Jun;161(6):802-10
Clinician Investigator, Princess Margaret Cancer Centre
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre